By proceeding, you agree to the storing of cookies on your device to enhance site navigation, analyse site usage, and assist in our marketing efforts. View our Privacy Policy for more information, or manage your preferences.

The WIND Trial

Our clinical research always builds on years of  research by leading neuroscientists, psychiatrists, pain specialists and clinicians, which you are welcome to review on our research page. Previous research had carefully documented the long-term safety and efficacy of neuromodulation on improving low mood and reducing pain symptoms, and  research by our collaborators, Prof Rodrigo Pegado (previously - Federal  University of Rio Grande do Norte, now - Harvard University) and Prof  Maria Micussi (previously - Federal University of Rio Grande do Norte,  now - Harvard University) had shown that using menstrual neuromodulation  therapy for five days before menstruation reduces pain symptoms in up  to 89% of users, and improves PMS symptoms in up to 84% of users with continued and consistent use.

Running  clinical trials takes time, so in late 2022 we set up an independent  collaboration with Prof Pegado and Prof Micussi to lead our clinical  trials investigating the short-term (single period intervention) effects  of using Nettle for alleviating both PMS and menstrual pain symptoms in  women experiencing menstrual pain (primary dysmenorrhea) and  premenstrual syndrome (measured with the PSST scale); and now the  results are in.In our WIND (At-home Treatment of Primary Dysmenorrhea using a Wearable IoT Neuromodulation Device: A Triple-Blind, Randomised Sham-Controlled Trial) study, we focused on 3 core metrics:

  • Reduction  of perceived pain, measured using a visual analog scale (score from  0-100) on the most painful day of the menstrual cycle (day 1 or day 2);
  • Improvement in low mood, measured using the PANAS negative scale, which assesses negative affect/emotion;
  • Improvement in functionality, or the ability to perform everyday tasks, measured using the 6-minute walking test.

We chose these metrics, because our users mentioned that it is the pain,  mood and functionality symptoms that impact their wellbeing the most during PMS and menstruation.

We then recruited women with both  menstrual pain and PMS symptoms, measured their symptoms for a baseline  period, then measured their symptoms after using Nettle daily for 5 days  prior to their next period, and then after a month, to see which  effects persist due to neuroplasticity and which don’t.

Our study was able to show that, just after a single month's use of Nettle:

The average period pain decreased by 53%

  • It kept decreasing over time, meaning that the overall highest  reduction could be predicted to happen after 3 months of consistent use  due to neuroplasticity effects.
  • Over 44% of women reported negligible period pain (pain reported as under 2/10) after a single month’s use.

The average low mood symptoms in the PMS period improved by 34%

  • 100% of users with extremely severe low mood symptoms (PANAS score above  25) improved to moderate or mild low mood symptoms after a single  month’s use of Nettle.
  • Low mood symptoms also showed neuroplastic effects (symptom relief  stayed for one more month after stopping the use of Nettle, and is  likely to improve with longer-term use).

The average functionality, or fitness status, improved by 11%

  • This is believed to be primarily linked to the reductions in pain and  anxiety, as well as improvements in mood, which lead to the ability to  be more active.
  • These improvements were directly linked to the use of Nettle and  disappear in the follow-up period, suggesting that it is not directly a  brain-based effect (but rather a secondary effect of the improvements in  the cycle-brain axis) which would be subject to neuroplasticity.

These results are incredibly exciting, as they show  that Nettle is able to reduce symptoms at least as effectively as  painkillers which reduce pain by 45-53% on  average, all while having none of the side effects. Additionally, it  also is able to improve mood and functionality - key PMS symptoms that  currently don’t have medical-grade treatments. This makes us confident  in claiming that Nettle truly is the world's first medical grade solution to PMS and menstrual pain.

These results and full methods  have been peer-reviewed and accepted for publication. Moreover,  although Nettle launches this summer, the research does not end here. A crucial part of our mission is to continue investing in research for  women's brain and physical health. Below are a few of the clinical trials we are actively participating in and setting up:

  • ENHANCE:  Endometriosis-Focused Study Helping to Alleviate Chronic Pelvic Pain in  Endometriosis Patients (double-blind, sham-controlled, in collaboration  with the NHS), June 2024-Jan 2025
  • TIARA: Targeting Inter-Hemispheric Alpha Coherence With Nettle To Treat PMDD in at-home settings, July 2023-August 2024
  • TETRIS: Targeting Elevated Theta With Nettle To Treat Primary Dysmenorrhea in at-home settings, July 2023-May 2024

We are looking forward to sharing this technology with you when Nettle launches later this year.

Join our waitlist to get early access to Nettle

Nettle launches summer 2024. Waitlist members will receive early access to our releases and exclusive offers. Keep an eye on our newsletter for the latest updates on our clinical trials and neuroscience content.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.